The Latest
Ascletis Submits Two IND Applications To The U.S. FDA For The Treatment Of Obesity: ASC36 Once-Monthly Injection, A Peptide Amylin Receptor Agonist, And ASC36_35 FDC Once-Monthly Injection, A Co-Formulation Of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35
Ascletis has filed two IND applications with the U.S. FDA for its obesity drugs, ASC36 and ASC36_35, marking a key step in clinical development.